User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

7484

Interactions with Platform & by Email *

INTERACTIONS

1048

Unique # Participated *

PARTICIPANTS

225

Responses Validated *

VALIDATIONS

43

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability And Reporting Limitations .....I-1  
   Disclaimers .....I-2
Data Interpretation & Reporting Level .....I-2
  
   Quantitative Techniques & Analytics .....I-3
Product Definitions And Scope Of Study .....I-3
  
   Outlook & Trends.....II-1
Targeted Therapies Bridge Therapeutic Gap.....II-1
Significant Unmet Medical Need Drives Growth.....II-1
1$100
   Herceptin Makes Headway as a Breakthrough Breast Cancer Therapeutic.....II-2
Aromatase Inhibitors Dethrone Tamoxifen’s Gold-Standard Status.....II-2
1$100
   Biotechnology Makes its Presence Felts.....II-3
Toxicity of Chemotherapeutic Agents In the Spotlight.....II-3
1$100
   Pipeline Diversity Ranging from Novel Cytotoxics to Metronomic Therapy.....II-4
Advances in Screening, Testing and Diagnosis Exert Positive Impact.....II-4
1$100
   Fundamental Trends Fuel Demand for Quality Healthcare.....II-5
Pharmaceutical Industry Faces Aggressive Pricing Regulations.....II-5
An Overview of the Pharmaceutical and Oncology Markets.....II-5
Pharmaceutical Industry: A Review.....II-5
A Note on the Pharma Industry.....II-5
1$100
   2005 in a Nutshell.....II-6
Market Issues.....II-6
Cost Control: A Major Hurdle.....II-6
Price Controls: Companies under Pressure.....II-6
1$100
   United States.....II-7
Europe.....II-7
Japan.....II-7
Cross-Border Selling: Widespread Phenomena.....II-7
The Process of Approval.....II-7
1$100
   Competitive Landscape.....II-8
A Brief Study of the Oncology Sector.....II-8
Competition in the Cancer Therapeutics Market.....II-8
1$100
   Table 1: Share of Leading Players in the Global Cancer Therapeutics Market: 2000 & 2005 (includes corresponding Graph/Chart).....II-91$300
   Market Landscape in Breast Cancer Therapeutics.....II-10
Global Breast Cancer Therapeutics Market.....II-10
Pharma Powerhouses Dominate Breast Cancer Therapeutics.....II-10
Table 2: Global Sales of Leading Breast Cancer Drugs: 2003-2005 (US$ Million) (includes corresponding Graph/Chart).....II-10
1$300
   Table 3: Global Market Share of Companies Offering Breast Cancer Therapeutics: 2004 (includes corresponding Graph/Chart).....II-11
Why do the Top Three have a Lion’s Share?.....II-11
Table 4: Percent Share of Global Breast Cancer Therapies by Type – Chemotherapy, Hormonals and Innovatives: 2006E (includes corresponding Graph/Chart).....II-11
1$300
   Table 5: Share of Various Treatment Regimens in the Breast Cancer Market: 2001 (includes corresponding Graph/Chart).....II-12
Hormonal Therapy Segment.....II-12
Global Hormonal Therapeutics.....II-12
Table 6: Global Share of Hormonal Therapeutics in Breast Cancer: 2002 & 2005 (includes corresponding Graph/Chart).....II-12
1$300
   Table 7: Global Aromatase Inhibitor Sales in Adjuvant and Metastatic Settings (US$ Million): 2003 .....II-13
Arimidex.....II-13
Table 8: Global Sales of Aromatase Inhibitor – Arimidex: 1998-2005 (US$ Million) (includes corresponding Graph/Chart).....II-13
Femara.....II-13
1$300
   Table 9: Global Sales of Aromatase Inhibitor – Femara: 1998 -2006 (US$ Million) (includes corresponding Graph/Chart).....II-14
Aromasin.....II-14
Table 10: Global Sales of Aromatase Inhibitor – Aromasin: 2001-2006 (US$ Million) (includes corresponding Graph/Chart).....II-14
Nolvadex.....II-14
Table 11: Global Sales of Tamoxifen (Nolvadex): 1997-2005 (US$ Million) (includes corresponding Graph/Chart).....II-14
1$300
   Faslodex.....II-15
Table 12: Global Sales of Faslodex: 2002-2005 (US$ Million) (includes corresponding Graph/Chart).....II-15
Zoladex.....II-15
Table 13: Global Sales of Zoladex: 2000-2005 (US$ Million) (includes corresponding Graph/Chart).....II-15
Chemotherapy Segment.....II-15
Table 14: Estimated Share of Various Chemotherapeutics in Breast Cancer: 2002 (includes corresponding Graph/Chart).....II-15
1$300
   Table 15: Global Sales of Anthracyclines – Epirubicin, Doxorubicin, Idarubicin, Daunorubicin: 2002 (US$ Million) (includes corresponding Graph/Chart).....II-16
Targeted Therapy Segment.....II-16
Table 16: Global Sales of Herceptin: 1999-2006 (US$ Million) (includes corresponding Graph/Chart).....II-16
Competitive Factors.....II-16
1$300
   History in a Nutshell.....II-17
Anatomy of the Breast.....II-17
What is Breast Cancer?.....II-17
1$100
   Origin.....II-18
Symptoms.....II-18
Stages.....II-18
Spread.....II-18
1$100
   Pathology.....II-19
Ductal Cancer.....II-19
In Situ.....II-19
Invasive.....II-19
Lobular Cancer.....II-19
In-Situ.....II-19
Invasive.....II-19
Others.....II-19
Inflammatory Cancer.....II-19
Paget’s Disease.....II-19
1$100
   Prognosis.....II-20
Factors for Good Prognosis.....II-20
Factors for Poor Prognosis.....II-20
Statistics on Breast Cancer Incidence Worldwide.....II-20
Terminology.....II-20
Incidence Statistics: What the Numbers Mean?.....II-20
1$100
   Table 17: New Breast Cancer Cases Worldwide by Region/Country – Western World (US, Canada, Japan, European Union), Developing Nations and Others: 2005 (includes corresponding Graph/Chart).....II-21

Table 18: Estimated Number of New Breast Cancer Cases/Deaths Worldwide: 2000 (includes corresponding Graph/Chart).....II-21
1$300
   Table 19: Age-Adjusted Death Rates in Female Breast Cancer Worldwide - by Select Countries: 2002 (Per 100,000 Population) (includes corresponding Graph/Chart).....II-22
Prevalence Patterns.....II-22
Incidence Rates: Rising Worldwide.....II-22
1$300
   Occurrence of Male Breast Cancer.....II-23
Survival: A Critical Factor.....II-23
Table 20: Five-Year Survival Rate by Cancer Stages (includes corresponding Graph/Chart).....II-23

Table 21: Five-Year Survival Rate for Local, Regional and Metastasized Cancer.....II-23
1$300
   Risk Factors.....II-24
Geographical Variances.....II-24
Age.....II-24
Table 22: Age and Breast Cancer Incidence.....II-24
1$300
   Table 23: Global Population of Women Aged 65 years and Above by Region – North America, Japan, Europe, Asia, Latin America and Rest of World: 2005E (includes corresponding Graph/Chart).....II-25

Table 24: Global Population of Women Aged 65 years and Above by Select Countries – US, Canada, Japan, France, Germany, UK, Italy, Spain, Russia, China, India, Argentina, Brazil, Mexico and South Africa (In Thousands) (includes corresponding Graph/Chart).....II-25
Reproductive Factors.....II-25
1$300
   Age at First Full-Term Pregnancy.....II-26
Genetic Predisposition.....II-26
Breast Condition.....II-26
Radiation.....II-26
Fat Intake.....II-26
Weight or Obesity.....II-26
1$100
   Alcohol Consumption.....II-27
Intake of Hormones.....II-27
Hormone Replacement Therapy.....II-27
Screening and Diagnosis.....II-27
Mammography Screening.....II-27
The Technique.....II-27
Types.....II-27
Screening Mammography.....II-27
1$100
   Diagnostic Mammography.....II-28
Digital Mammography.....II-28
Full-Field Digital Mammography.....II-28
Trends in Mammography.....II-28
Digital Systems Drive Market Growth.....II-28
1$100
   Diagnostic Investigations.....II-29
Breast Self-Examination.....II-29
Clinical Breast Examination.....II-29
Biopsy.....II-29
Needle Biopsy.....II-29
Sentinel Lymph Node Biopsy.....II-29
Steriotactic Needle Biopsy.....II-29
Other Diagnostic Techniques.....II-29
DOBI Medical’s Dynamic Optical Breast Imaging (DOBI).....II-29
1$100
   Hologic’s 3-D Tomosynthesis.....II-30
Patient Awareness & Education.....II-30
1$100
   Therapy Types.....II-31
A Complex Disease with Multiple Treatment Options.....II-31
Flowchart of Treatment Options for Metastatic and Non-Metastatic Breast
  Cancer.....II-31
2$200
   Breast Cancer Treatments (All Types) for Various Stages.....II-33
Factors that Determine Therapeutic Conduct.....II-33
1$100
   A Study of Various Therapy Types.....II-34
Definitions and Scope.....II-34
Hormonal Therapy.....II-34
What is Endocrine/Hormonal Therapy?.....II-34
1$100
   The Biochemical Process of Sex hormones.....II-35
What are the Drug Categories?.....II-35
Categories of Hormonal Agents.....II-35
1$100
   Hormonal Therapies and their Indications.....II-36
An Analysis of Hormonal Drug Classes.....II-36
SERM.....II-36
Mechanism of Action.....II-36
Products in the Drug Class.....II-36
1$100
   Nolvadex (Tamoxifen).....II-37
Evista (Raloxifene).....II-37
Fareston (Toremifene).....II-37
Arzoxifene.....II-37
SERD.....II-37
Mechanism of Action.....II-37
1$100
   Products in the Drug Class.....II-38
Faslodex (Fulvestrant).....II-38
Differences in ERDs and SERMs.....II-38
Aromatase Inhibitors.....II-38
History.....II-38
1$100
   Mechanism of Action.....II-39
Products in the Drug Class.....II-39
Arimidex (Anastrozole).....II-39
Femara (Letrozole).....II-39
1$100
   Aromasin (Exemestane).....II-40
Differences Among the Trio.....II-40
Costs.....II-40
Table 25: Comparative Cost of Tamoxifen and Aromatase Inhibitors in the US and Europe (includes corresponding Graph/Chart).....II-40
1$300
   LHRH Analogs.....II-41
The Pituitary-Gonadal System.....II-41
What are LHRH Analogs?.....II-41
LHRH Agonists vs. Antagonists.....II-41
Products in the Drug Class.....II-41
Lupron (Leuprolide).....II-41
1$100
   Zoladex (Goserelin Acetate).....II-42
Progestogens.....II-42
Ovarian Shutdown and Removal.....II-42
1$100
   Target Audience.....II-43
Where is it Used?.....II-43
Choosing the Right Therapeutic Strategy.....II-43
1$100
   Side Effects.....II-44
Duration of Therapy.....II-44
1$100
   Therapy Types.....II-45
Adjuvant Hormonal Therapy.....II-45
Neoadjuvant Hormonal Therapy.....II-45
Metastatic Hormonal Therapy.....II-45
Benefits.....II-45
Advances.....II-45
1$100
   Comparative Study of Hormonal Therapies.....II-46
Aromatase Inhibitors vis-à-vis SERMs.....II-46
SERMs, Aromatase Inhibitors, and SERDs.....II-46
1$100
   Pivotal Clinical Trials.....II-47
ATAC Trial: Arimidex, Tamoxifen Alone or in Combination.....II-47
Replacing Tamoxifen with Anastrozole.....II-47
Hormone Receptor Status and Endocrine Therapy.....II-47
1$100
   Extended Adjuvant Endocrine Therapy.....II-48
Neoadjuvant Endocrine Therapy.....II-48
Austrian Breast and Colorectal Cancer Study Group [ABSCG]-8/Arimidex-Nolvadex
  [ARNO]-95 trials.....II-48
1$100
   Italian Tamoxifen-Arimidex (ITA) trial.....II-49
STAR: Study of Tamoxifen and Raloxifene.....II-49
IBIS: International Breast Cancer Intervention Studies.....II-49
IBIS I.....II-49
IBIS II.....II-49
1$100
   IES: Intergroup Exemestane Study.....II-50
MA 17 Study.....II-50
BIG 1-98.....II-50
1$100
   Chemotherapy.....II-51
What is Chemotherapy?.....II-51
Efficacy.....II-51
Areas of Use.....II-51
1$100
   Adjuvant Setting.....II-52
Neoadjuvant Setting.....II-52
Metastatic Setting.....II-52
Classes of Cytotoxic Agents.....II-52
1$100
   Cell Cycle and Effects of Cytotoxics on Various Phases.....II-53
Cytotoxic Drug Classes and Mode of Action.....II-53
Anthracyclines.....II-53
Description.....II-53
Mode of Action.....II-53
1$100
   Products in the Drug Class.....II-54
Doxorubicin and Epirubicin.....II-54
Side Effects.....II-54
Mitotic Inhibitors.....II-54
Description and Mechanism of Action.....II-54
1$100
   Current Research Activity.....II-55
Taxanes & Vinca Alkaloids.....II-55
Mechanism of Action – Taxanes.....II-55
Products in the Drug Class.....II-55
Abraxane (albumin-bound paclitaxel).....II-55
A Breakthrough Formulation.....II-55
1$100
   The Product and the Technology.....II-56
Abraxane Eliminates Solvent Related Toxicity.....II-56
How does nab T Technology Work?.....II-56
Clinical Trial Data.....II-56
1$100
   Current Approval.....II-57
Taxotere (Docetaxel).....II-57
Taxol(Paclitaxel).....II-57
Vinorelbine.....II-57
1$100
   Antimetabolites.....II-58
Description.....II-58
Mechanism of Action.....II-58
Types.....II-58
Purine Analogues.....II-58
Folic Acid Analogues.....II-58
Products in the Drug Class.....II-58
Xeloda (Capecitabine).....II-58
Xeloda and Taxotere Combination Therapy.....II-58
1$100
   Xeloda Monotherapy.....II-59
Gemzar (Gemcitabine).....II-59
New Developments.....II-59
Alkylating Agents.....II-59
Description.....II-59
Mechanism of Action.....II-59
1$100
   Classes of Alkylating Agents.....II-60
Nitrosoureas.....II-60
1$100
   Topoisomerase II Inhibitors.....II-61
Other Chemotherapy Drugs.....II-61
A Compilation of Various Chemotherapeutic Agents.....II-61
3$300
   Common Chemotherapy Regimens.....II-64
Established and Emerging Regimens.....II-64
CMF.....II-64
TAC & FAC.....II-64
CA Followed by Trastuzumab + Paclitaxel.....II-64
High-Dose Chemo with Peripheral-Blood Stem-Cell or Bone Marrow
  Transplantation.....II-64
Side Effects Associated with Cytotoxic Agents.....II-64
1$100
   Overcoming Cytotoxic Resistance.....II-65
Immunotherapy.....II-65
The Concept of Immunotherapy.....II-65
Cancer Vaccines.....II-65
1$100
   Breast Cancer Vaccine Pipeline.....II-66
Monoclonal Antibodies.....II-66
Types of Monoclonal Antibodies.....II-66
Mechanism of Action.....II-66
Herceptin – A Potential Blockbuster.....II-66
About HER2+Breast Cancer.....II-66
1$100
   Incidence of HER2+ Cases.....II-67
What is Herceptin?.....II-67
Herceptin its Indications.....II-67
Potential for Herceptin.....II-67
Where is it Indicated?.....II-67
Current Areas of Indication.....II-67
1$100
   Use in Metastatic and Non-Metastatic Stages.....II-68
For Metastatic Indication.....II-68
For Non-Metastatic Disease.....II-68
Mechanism of Action.....II-68
Toxicity Profile.....II-68
1$100
   Therapy Determination Tests.....II-69
IHC.....II-69
FISH.....II-69
Global Availability.....II-69
Global and Regional Marketers.....II-69
Studies Evaluating Efficacy of Herceptin.....II-69
HERA Study.....II-69
1$100
   M77001 Study Group Trial.....II-70
B-31 and N9831Clinical Trials.....II-70
Novel Therapy.....II-70
What are Novel Therapeutics?.....II-70
1$100
   Drugs Targeting Receptors/Pathways Active in Breast Cancer.....II-71
Avastin – In the Wings.....II-71
Product Description.....II-71
Avastin and its Indications.....II-71
1$100
   Avastin Breast Cancer Trials.....II-72
Market Issues.....II-72
Disappointments Galore in the Anti-Angiogenesis Area.....II-72
1$100
   Growth Factor Inhibitors.....II-73
ErbB-2 Inhibitors.....II-73
EGFR Inhibitors.....II-73
Angiogenesis Inhibitors.....II-73
The Process.....II-73
Drugs under Development.....II-73
Lapatinib (previously GW572016).....II-73
Iressa (Gefitinib).....II-73
1$100
   MEK Inhibitors/Farnesyl Transferase.....II-74
Targeting Apoptosis.....II-74
Antisense Technology.....II-74
1$100
   Targeting mTOR Pathway.....II-75
Radiation Therapy.....II-75
Definition.....II-75
Types of Radiotherapy.....II-75
Whole-Breast External Beam Radiation Therapy.....II-75
Accelerated Partial Breast Irradiation Therapy.....II-75
1$100
   Side Effects.....II-76
Notable Products.....II-76
Cytokinetics’ MammoSite Radiation Therapy System.....II-76
1$100
   Surgery.....II-77
Conventional Treatment Method.....II-77
Types of Surgical Procedures.....II-77
Lumpectomy.....II-77
Mastectomy.....II-77
1$100
   Table 26: Five-Year Survival Rate Based on Type of Surgery (includes corresponding Graph/Chart).....II-78
Breast Reconstruction.....II-78
Palliation and Support.....II-78
1$300
   Product Development Timeline and Clinical Stages.....II-791$100
   Pipeline Drugs (Phases I, II and III) and their Clinical Status.....II-803$300
   Tests Available or under Development.....II-83
BioLabs’ Mammastatin Serum Assay (MSA).....II-83
Agendia’s MammaPrint Test.....II-83
Matritech’s Nuclear Matrix Protein (NMP66).....II-83
Power3 Medical Products’ NAF Test.....II-83
Genomics Health’s Oncotype DX.....II-83
1$100
   Use of DNA Microarray with a Chemotherapeutic Agent.....II-84
Novel Therapeutic Technologies.....II-84
Gene Expression Profiling.....II-84
Genetic Testing.....II-84
Biomarkers.....II-84
Types and Significance.....II-84
1$100
   Blood and Body Fluids as Biomarkers.....II-85
Hybrid Assays.....II-85
CTC Detection.....II-85
Prediction of Therapeutic Response and Prognosis.....II-85
1$100
   Proteomics.....II-86
1$100
   Abraxis Bioscience Inc, US .....II-87
Aeterna Zentaris Inc, Canada.....II-87
Agendia BV, The Netherlands.....II-87
1$100
   Aphton Corp, US.....II-88
Array BioPharma Inc, US.....II-88
AstraZeneca Plc, UK.....II-88
Bristol Myers Squibb, US.....II-88
Dendreon Corporation, US.....II-88
1$100
   Eli Lilly and Company, US.....II-89
Genentech Inc, US.....II-89
Genta Inc, US.....II-89
Novartis AG, Switzerland.....II-89
1$100
   Pfizer Inc, US.....II-90
Roche Group, Switzerland.....II-90
Sanofi-Aventis, France.....II-90
Schering AG, Germany.....II-90
1$100
   Therion Biologics Corporation, US.....II-91
ViRexx Medical Corp, Canada.....II-91
1$100
   EC Approves Herceptin for Early Stage Adjuvant Treatment.....II-92
Novartis and Chugai Pharmaceuticals Introduce Femara in Japan.....II-92
Abraxane Receives Canadian Approval for Metastatic Breast Cancer.....II-92
Roche Files Marketing Authorization Application for Early-Stage Herceptin
  Therapy.....II-92
Genentech and Roche Submit Avastin sBLA for Metastatic Breast Cancer.....II-92
1$100
   Abraxane Receives Approval in the US for Metastatic Breast Cancer.....II-93
Femara Approved in the US for Early Adjuvant Setting.....II-93
Aromasin Approved for Adjuvant Use in Early Breast Cancer.....II-93
1$100
   Femara Approved in UK for Early-Stage Breast Cancer.....II-94
Schering Commences Three Phase 2 Clinical Trials with ZK-EPO.....II-94
1$100
   AstraZeneca and Schering Collaborate for SERD Breast Cancer Drug.....II-95
Bayer to Acquire Schering AG .....II-95
AstraZeneca in Co-Promotion Agreement with Abraxis.....II-95
American Pharmaceutical Partners and American BioScience Merge to Form Abraxis
  BioScience.....II-95
1$100
   AstraZeneca Acquires KuDOS Pharmaceuticals.....II-96
BioMérieux and ExonHit Therapeutics in Research Collaboration.....II-96
Biomedical Diagnostics Signs Up with Harlan Bioproducts for Science.....II-96
bioMerieux to Use Affymetrix’ GeneChip Technology in Breast Cancer
  Diagnostics.....II-96
YM BioSciences Signs a Collaborative Agreement with Sanofi-Aventis.....II-96
1$100
   Genesis BioVentures and Corgenix to Merge.....II-97
Celera Diagnostics Forms Research Collaboration with Merck.....II-97
1$100
   Table 27: Global Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-98

Table 28: Global 10-Year Perspective for Breast Cancer Therapeutics by Geographic Region – US, Europe and Rest of World Markets for 2000, 2006, and 2010 (includes corresponding Graph/Chart).....II-98
1$300
   Table 29: Global Recent Past, Current & Future Analysis for Breast Cancer Hormonal Therapy by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-99

Table 30: Global 10-Year Perspective for Breast Cancer Hormonal Therapy by Geographic Region – US, Europe and Rest of World Markets for 2000, 2006, and 2010 (includes corresponding Graph/Chart).....II-99
1$300
   Table 31: Global Recent Past, Current & Future Analysis for Breast Cancer Chemotherapy by Geographic Region – US, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-100

Table 32: Global 10-Year Perspective for Breast Cancer Chemotherapy by Geographic Region – US, Europe and Rest of World Markets for 2000, 2006, and 2010 (includes corresponding Graph/Chart).....II-100
1$300
   Table 33: Global Recent Past, Current & Future Analysis for Breast Cancer Innovative Therapy by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....II-101

Table 34: Global 10-Year Perspective for Breast Cancer Innovative Therapy by Geographic Region – US and Rest of World Markets for 2000, 2006 and 2010.....II-101
1$300
   A. Market Analysis.....III-1
Outlook and Trends.....III-1
Aromatase Inhibitors on an Upward Trajectory.....III-1
Table 35: Market Share of SERMs and Aromatase Inhibitors in the US: 2005 (includes corresponding Graph/Chart).....III-1
1$150
   Table 36: Market Share of Aromatase Inhibitors in the US: 2005 (includes corresponding Graph/Chart).....III-2
Immense Potential Exists for Innovatives/Targeted Therapy.....III-2
Table 37: US Sales of Herceptin: 1998- 2005 (US$ Million) (includes corresponding Graph/Chart).....III-2
New Chemotherapeutic Agents Feature Reduced Toxicity.....III-2
1$150
   Patent Expiries Encourage Interest in Biotech Products .....III-3
Growth Backed by New Product Approvals and Expanded Indications .....III-3
Adjuvant Settings Emerge as a Promising Area.....III-3
Patient Population.....III-3
Innovative Therapy.....III-3
Herceptin.....III-3
Avastin .....III-3
1$75
   Surgery.....III-4
US Market Dynamics.....III-4
TNM Classification.....III-4
1$75
   TNM Grouping by Stage, Tumor Size, Nodal Involvement and Risk.....III-5 1$75
   Table 38: Percentage of Patients by Stage of Diagnosis in the US: Share by Stage – 2005 (includes corresponding Graph/Chart).....III-6
Incidence.....III-6
1$150
   Statistics.....III-7
Table 39: Leading Types of Female Cancers in the US - % of New Cases and Deaths: 2005 (includes corresponding Graph/Chart).....III-7

Table 40: Estimated Number of New Female Breast Cancer Cases and Deaths in the US: 1997-2006E (includes corresponding Graph/Chart).....III-7
1$150
   Table 41: Estimated New Female Breast Cancer Cases in Top 20 States in the US: 2000-2005 (includes corresponding Graph/Chart).....III-81$150
   Table 42: Estimated Female Breast Cancer Deaths in Top 20 States in the US: 2000-2005 (includes corresponding Graph/Chart).....III-9
Risk Factors.....III-9
1$150
   High, Medium and Low Risk Factors Associated with Breast Cancer.....III-10
Risk of Developing Breast Cancer: US Data.....III-10
1$75
   Ethnicity.....III-11
Table 43: Leading Types of Cancers in African American Females – % of New Cases and Deaths: 2005E (includes corresponding Graph/Chart).....III-11
1$150
   Table 44: Staged Distribution for Female Breast Cancer in African American and Whites: 1995-2000 (includes corresponding Graph/Chart).....III-12

Table 45: Female Breast Cancer Incidence and Death Rates (age-adjusted) by Race and Ethnicity, US: 1998-2002 (includes corresponding Graph/Chart).....III-12
1$150
   Table 46: US-Five Year Relative Survival Rates in African American and White Females by Stage: 1995-2000 (includes corresponding Graph/Chart).....III-13

Table 47: Leading Causes of Disease-Related Deaths Among US Hispanics: 2000 (includes corresponding Graph/Chart).....III-13
1$150
   Table 48: Leading Types of Cancers in Hispanic Females – % of New Cases and Deaths: 2003E (includes corresponding Graph/Chart).....III-14
Family History.....III-14
Hereditary Factors .....III-14
1$150
   Hormone Replacement Therapy.....III-15
Breast Biopsy.....III-15
Breast Radiation.....III-15
Menstrual Periods.....III-15
Diethylstilbestrol.....III-15
Lifestyle.....III-15
Breast-Feeding.....III-15
1$75
   Physical Activity.....III-16
Genetic Testing.....III-16
Other Factors.....III-16
Survival Rates and its Implications.....III-16
Relative Survival Rates.....III-16
Table 49: Five-year Relative Survival Rates Among Female Breast Cancer Patients Based on the Number of Years Since Diagnosis (includes corresponding Graph/Chart).....III-16
1$150
   Table 50: Five-year Relative Survival Rates Among Female Breast Cancer Patients Based on Age at Diagnosis (includes corresponding Graph/Chart).....III-17
Process of Therapy.....III-17
1$150
   A Focus on Mammography.....III-18
Highest Number of Screening Procedures Worldwide.....III-18
Table 51: Mammography in Women Aged 40 and Above:US (2000).....III-18

Table 52: Estimated Prices of Breast Cancer Testing Modalities in the US.....III-18
1$150
   Regulatory Forces Shape Mammography Fortunes.....III-19
USPSTF Recommends Mammography for Women Over 40.....III-19
Competitive Dynamics of Regulatory, Prescription and Reimbursement Issues.....III-19
Pharmaceutical Registration Process in the US.....III-19
1$75
   An Overview of Regulatory Scenario in the US.....III-201$75
   New Regulations Intensify Competitive Conditions.....III-21
Prescription Conduct: Under Scrutiny.....III-21
Generic Medicines Preferred to Branded Medicines.....III-21
1$75
   A Review of Select Medical Acts.....III-22
Medicare Prescription Drug, Improvement and Modernization Act .....III-22
Medicare Prescription Drug Benefit.....III-22
1$75
   Medicaid Program.....III-23
Women's Health and Cancer Rights Act .....III-23
Women’s Health and Wellness Act.....III-23
Mammography Quality and Standards Act.....III-23
Reimbursement Issues Concerning Oncology Therapies.....III-23
1$75
   Male Breast Cancer.....III-24
Anatomy.....III-24
Symptoms.....III-24
Types of Breast Cancer .....III-24
Treatment.....III-24
Incidence.....III-24
1$75
   Table 53: Estimated Number of New Male Breast Cancer Cases and Deaths: 1997-2006E (includes corresponding Graph/Chart).....III-25
Mortality and Survival.....III-25
ASCO Trials.....III-25
Major Breast Cancer Trials for Key Products Conducted by ASCO.....III-25
2$300
   B. Market Analytics.....III-27
Table 54: US Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy, Chemotherapy and Innovative Therapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-27

Table 55: US 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy, Chemotherapy and Innovative Therapy Markets for 2000, 2006, and 2010 (includes corresponding Graph/Chart).....III-27
1$150
   A. Market Analysis.....III-28
Incidence.....III-28
Table 56: Proportion of New Breast Cancer Cases (by Stage) in Europe At Diagnosis: 2005 (includes corresponding Graph/Chart).....III-28
Mortality and Survival.....III-28
1$150
   Table 57: Age-Adjusted Death Rates Per 100,000 Population Due to Female Breast Cancers in Europe - by Select Countries: 2002 (includes corresponding Graph/Chart).....III-29
Demographics.....III-29
Table 58: Population of Women Aged 65 years and Above by Country - Russia, Germany, Italy, France, UK, Spain, Poland, The Netherlands, Belgium, Hungary, Czech Republic, Sweden, Austria, Switzerland, Finland, Denmark and Norway: 2005E (In Thousands) (includes corresponding Graph/Chart).....III-29
1$150
   Screening and Diagnosis.....III-30
Reimbursement of Mammography Procedures.....III-30
Market Trends.....III-30
Rapid Uptake of Aromatase Inhibitors .....III-30
Chemotherapy Targets Hormone Negative Cancers.....III-30
1$75
   Innovative/Targeted therapy: Still on the Fringes .....III-31
Market Structure.....III-31
Table 59: Market Share of Companies in the European Hormonals Segment: 2002 (In terms of Sales) (includes corresponding Graph/Chart).....III-31

Table 60: Market Share of Companies in the European Chemotherapy Segment: 2002 (In terms of Sales) (includes corresponding Graph/Chart).....III-31
1$150
   Opportunities and Challenges Presented by the Therapeutics Market.....III-32
Pharmaceutical Registration Process in Europe.....III-32
Mutual Recognition Procedure.....III-32
Centralized Procedure.....III-32
1$75
   Reimbursement Scenario.....III-33
Aggressive Efforts Underway to Control Healthcare Costs.....III-33
1$75
   B. Market Analytics.....III-34
Table 61: European Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Geographic Region –France, Germany, Italy, UK, Spain & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-34

Table 62: European 10-Year Perspective for Breast Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain & Rest of Europe Markets for 2000, 2006, and 2010 (includes corresponding Graph/Chart).....III-34
1$150
   Table 63: European Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-35

Table 64: European 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010.....III-35
1$150
   A. Market Analysis.....III-36
Highlights.....III-36
Market Structure.....III-36
Table 65: Market Share of Companies in the French Chemotherapeutic Segment: 2002 (includes corresponding Graph/Chart).....III-36

Table 66: Market Share of Companies in the French Hormonal Therapy Segment: 2002 (includes corresponding Graph/Chart).....III-36
1$150
   Regulatory Structure.....III-371$75
   B. Market Analytics.....III-38
Table 67: French Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-38

Table 68: French 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010.....III-38
1$150
   A. Market Analysis.....III-39
Snapshots.....III-39
Market Share Data .....III-39
Table 69: Share of Companies in the German Breast Cancer Therapeutics Market: 2002 (includes corresponding Graph/Chart).....III-39

Table 70: Market Share of Companies in the German Chemotherapeutic Segment: 2002 (includes corresponding Graph/Chart).....III-39
1$150
   Table 71: Market Share of Companies in the German Hormonal Therapy Segment: 2002 (includes corresponding Graph/Chart).....III-40
Regulatory Scenario.....III-40
1$150
   B. Market Analytics.....III-41
Table 72: German Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-41

Table 73: German 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010.....III-41
1$150
   A. Market Analysis.....III-42
Highlights.....III-42
1$75
   Epidemiological Data.....III-43
Table 74: Number of Female New Breast Cancer Cases and Deaths in the UK: 1993-2002 (includes corresponding Graph/Chart).....III-43

Table 75: Most Common Female Cancers in the UK: 2002 (includes corresponding Graph/Chart).....III-43
1$150
   Table 76: Number of New Female Breast Cancer Cases Diagnosed in the UK: 2000 (includes corresponding Graph/Chart).....III-44

Table 77: Number of Female Breast Cancer Deaths in the UK: 2002 (includes corresponding Graph/Chart).....III-44
1$150
   Issues & Trends.....III-45
Aromatase Inhibitors: On the Recommendation List.....III-45
Massive Government Efforts to Enhance Breast Cancer Awareness.....III-45
Implementation of the National Screening Program.....III-45
Reimbursement and Regulatory Environment.....III-45
1$75
   Competition.....III-46
Table 78: Market Share of Companies in the UK Chemotherapeutic Segment: 2002 (includes corresponding Graph/Chart).....III-46

Table 79: Market Share of Companies in the UK Hormonal Therapy Segment: 2002 (includes corresponding Graph/Chart).....III-46
1$150
   B. Market Analytics.....III-47
Table 80: UK Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-47

Table 81: UK 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010.....III-47
1$150
   A. Market Analysis.....III-48
Market Snippets.....III-48
Competitive Framework.....III-48
Table 82: Market Share of Companies in the Italian Chemotherapeutic Segment: 2002 (includes corresponding Graph/Chart).....III-48

Table 83: Market Share of Companies in the Italian Hormonal Therapy Segment: 2002 (includes corresponding Graph/Chart).....III-48
1$150
   Regulatory Scenario.....III-491$75
   B. Market Analytics.....III-50
Table 84: Italian Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-50

Table 85: Italian 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010.....III-50
1$150
   A. Market Analysis .....III-51
Snapshots .....III-51
Market Participants.....III-51
Table 86: Share of Companies in the Spanish Breast Cancer Therapeutics Market: 2002 (includes corresponding Graph/Chart).....III-51

Table 87: Market Share of Companies in the Spanish Chemotherapeutic Segment: 2002 (includes corresponding Graph/Chart).....III-51
1$150
   Table 88: Market Share of Companies in the Spanish Hormonal Therapy Segment: 2002 (includes corresponding Graph/Chart).....III-52
Regulatory Scenario.....III-52
1$150
   B. Market Analytics.....III-53
Table 89: Spanish Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-53

Table 90: Spanish 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010.....III-53
1$150
   A. Market Analysis .....III-54
Highlights .....III-54
B. Market Analytics.....III-54
Table 91: Rest of Europe Recent Past, Current & Future Analysis for Breast Cancer Therapeutics by Product Segment - Hormonal Therapy and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-54
1$150
   Table 92: Rest of Europe 10-Year Perspective for Breast Cancer Therapeutics by Product Segment- Hormonal Therapy and Chemotherapy Markets for 2000, 2006, and 2010.....III-55
1$150
   A. Market Analysis.....III-56
Outlook.....III-56
Focus on Select Regions.....III-56
Canada.....III-56
Highlights.....III-56
1$75
   Table 93: Breast Cancer Incidence in Canada by Age Group: 2006E.....III-57

Table 94: Breast Cancer Mortality in Canada by Age Group: 2006E (includes corresponding Graph/Chart).....III-57

Table 95: Breast Cancer Incidence and Mortality in Canada by Age Group: 2005 (includes corresponding Graph/Chart).....III-57
1$150
   Table 96: New Cases of Breast Cancer in Canada, By Age Group: 2004 (includes corresponding Graph/Chart).....III-58

Table 97: Breast Cancer Deaths in Canada by Age Group: 2004 (includes corresponding Graph/Chart).....III-58
Japan.....III-58
Incidence.....III-58
Regulatory Environment.....III-58
An Overview.....III-58
1$150
   Expedited Approval for Marketed/Approved US and European Products .....III-59
Reimbursement and Pricing Issues.....III-59
Pharmaceutical Registration Process in Japan.....III-59
1$75
   Key Player.....III-60
Chugai Pharmaceutical Co.....III-60
Asia.....III-60
Demographics .....III-60
Table 98: Population of Women Aged 65 years and Above in Select Asian Countries – China, India, Indonesia, Thailand, South Korea, Australia and Taiwan:2005E (includes corresponding Graph/Chart).....III-60
1$150
   Table 99: Population of Women Aged 65 years and Above in Latin America – Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela: 2005E (includes corresponding Graph/Chart).....III-61

Table 100: Age-Adjusted Death Rates Per 100,000 Population Due to Female Breast Cancers in anada, Japan, Asia and Latin American Countries: 2002 (includes corresponding Graph/Chart).....III-61
Australia.....III-61
1$150
   China.....III-62
Highlights.....III-62
Market Size.....III-62
Table 101: Chinese Market for Breast Cancer Therapeutics with Annual Sales Figures in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart).....III-62
1$150
   India.....III-63
Latin America.....III-63
Ukraine.....III-63
1$75
   B. Market Analytics.....III-64
Table 102: Rest of World Recent Past, Current & Future Analysis for Breast Cancer Therapeutics with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart).....III-64
1$150